Paromomycin
From Ganfyd
rINN: Paromomycin
Other Names
Paromomycin sulfate, Humatin®, (2R,3S,4R,5R,6S)-5- amino -6-[(1R,2S,3S,4R,6S)-4,6- diamino -2-[(2S,3R,4R,5R)-4-[(2R,3R,4R,5R,6S)-3- amino -6- (aminomethyl) -4,5- dihydroxy-oxan-2-yl] oxy-3- hydroxy -5- (hydroxymethyl) oxolan -2- yl]oxy -3- hydroxy- cyclohexyl] oxy -2- (hydroxymethyl) oxane -3,4- diol
Pharmacological Information
Pharmacology Images
Web information on Paromomycin
Mechanism of Action
Inhibits protein synthesis by binding to 16S ribosomal RNA
Relevant Clinical Literature
UK Guidance
Regulatory Literature
Other Literature
Please read pharmacological data limitations
Other Wikis
Medpedia on Paromomycin (Less technical, good quality control)
Wikipedia on Paromomycin (Less technical, ? quality control)
Contents |
Introduction
Clinical Use
Used for its anti-parasite activity.
Indications
- Cryptosporidiosis
- Amoebiasis
- Visceral leishmaniasis
Administration
IV
Clinical Issues
Class Contraindications
Class Side-effects
- Ototoxicity
- Nephrotoxicity
- Impairment neuromuscular transmission
Aminoglycoside ototoxicity is associated with a genetic susceptibility in a third to a half of all cases. Most commonly mitochondrial – shows bacterial origin. Screening patients likely to need repeated courses eg CFs, chemotherapy patients, preterm neonates is feasible, but cost:benefit ratio? Consider costs of deafness, cochlear implant etc.
Class Interactions
- Enhanced ototoxicity with ototoxic diuretics eg furosemide.
